Key result
Sulodexide significantly improved the Initial Claudication Distance by +68.9 m (95% CI ± 11.9 m; p < 0.001) after 90 days of treatment in patients with peripheral arterial disease.
Why the study?
Increasing pain-free walking distance is a key prognostic and symptomatic goal in peripheral arterial disease, prompting a reassessment of whether sulodexide improves Initial Claudication Distance.
Does sulodexide improve Initial Claudication Distance in adult patients with peripheral arterial disease?
Meta-Analysis
Double-blind
Does sulodexide improve Initial Claudication Distance in adult patients with peripheral arterial disease?
Sulodexide significantly improves pain-free walking distance (Initial Claudication Distance) in patients with peripheral arterial disease after 90 days of treatment.
May support sulodexide for PAD symptom relief; confirms claudication benefit in meta-analysis.
Peripheral arterial disease is associated with very high cardiovascular risk. The main symptom is intermittent claudication, which strongly affects the quality of life. Therefore, treatment goals in peripheral arterial disease consist of the reduction of cardiovascular events and the relief of symptoms. An increase in pain-free walking distance, evaluated based on the Initial Claudication Distance, was also a strong positive prognostic factor in patients with peripheral arterial disease. Our objective was to reassess whether sulodexide is effective in improving Initial Claudication Distance. For this, we searched the literature according to the PRISMA checklist for double blind clinical trials assessing the improvement in the Initial Claudication Distance after 90 days of standard therapeutic regimen with sulodexide in adult patients with peripheral arterial disease. We found and assessed for bias in 11 studies eligible for review and meta-analysis. Data extracted from those studies favoured the sulodexide group, showing an overall difference in Initial Claudication Distance of +68.9 (CI 95%; ± 11.9 m) at the end of treatment (p < 0.001). According to this review, sulodexide is effective in improving Initial Claudication Distance and consequently the quality of life in patients with peripheral arterial disease. Further studies are needed to assess the effects of this drug on disease progression in asymptomatic patients with peripheral arterial disease.
No takes yet. Share an insight, caveat, or question.
Gaddi et al. (2020) conducted a meta-analysis in Peripheral arterial disease. Sulodexide was evaluated on Initial Claudication Distance (Difference +68.9, 95% CI ± 11.9 m, p=< 0.001). Sulodexide significantly improved the Initial Claudication Distance by +68.9 m (95% CI ± 11.9 m; p < 0.001) after 90 days of treatment in patients with peripheral arterial disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: